CA2520181A1 - Selected rna motifs to include cell death and/or apoptosis - Google Patents
Selected rna motifs to include cell death and/or apoptosis Download PDFInfo
- Publication number
- CA2520181A1 CA2520181A1 CA002520181A CA2520181A CA2520181A1 CA 2520181 A1 CA2520181 A1 CA 2520181A1 CA 002520181 A CA002520181 A CA 002520181A CA 2520181 A CA2520181 A CA 2520181A CA 2520181 A1 CA2520181 A1 CA 2520181A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- dsrna
- ssrna
- cat
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 77
- 230000030833 cell death Effects 0.000 title claims abstract description 72
- 210000004027 cell Anatomy 0.000 claims abstract description 220
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 181
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 132
- 230000001939 inductive effect Effects 0.000 claims abstract description 42
- 230000004044 response Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 33
- 108091034117 Oligonucleotide Proteins 0.000 claims description 23
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 15
- 201000006894 monocytic leukemia Diseases 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- 208000000389 T-cell leukemia Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000016396 cytokine production Effects 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- 229930024421 Adenine Natural products 0.000 claims description 6
- 229960000643 adenine Drugs 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 230000001640 apoptogenic effect Effects 0.000 claims description 5
- 229940104302 cytosine Drugs 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- 229930010555 Inosine Natural products 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 9
- 230000006698 induction Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 230000002062 proliferating effect Effects 0.000 abstract description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 46
- 239000012091 fetal bovine serum Substances 0.000 description 46
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 24
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 24
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 20
- 229960005542 ethidium bromide Drugs 0.000 description 20
- 239000002158 endotoxin Substances 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
- 229930182816 L-glutamine Natural products 0.000 description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 229940054269 sodium pyruvate Drugs 0.000 description 12
- 229960005322 streptomycin Drugs 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 11
- 239000012737 fresh medium Substances 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 230000004700 cellular uptake Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000003068 molecular probe Substances 0.000 description 9
- 229960003857 proglumide Drugs 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 5
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 5
- 208000003747 lymphoid leukemia Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 3
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011013 endotoxin removal Methods 0.000 description 3
- 102000055691 human APC Human genes 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000973510 Homo sapiens Melanoma-derived growth regulatory protein Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 2
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 2
- 201000011186 acute T cell leukemia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 101710193790 Tax1-binding protein 3 Proteins 0.000 description 1
- 102100036221 Tax1-binding protein 3 Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000017239 negative regulation of gene expression Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45774503P | 2003-03-26 | 2003-03-26 | |
| US60/457,745 | 2003-03-26 | ||
| US49778403P | 2003-08-26 | 2003-08-26 | |
| US60/497,784 | 2003-08-26 | ||
| PCT/US2004/009261 WO2004087877A2 (en) | 2003-03-26 | 2004-03-25 | Selected rna motifs to include cell death and/or apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2520181A1 true CA2520181A1 (en) | 2004-10-14 |
Family
ID=33135068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002520181A Abandoned CA2520181A1 (en) | 2003-03-26 | 2004-03-25 | Selected rna motifs to include cell death and/or apoptosis |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20060172959A1 (enExample) |
| EP (1) | EP1613775B1 (enExample) |
| JP (1) | JP2006522806A (enExample) |
| CN (1) | CN1795274A (enExample) |
| AU (1) | AU2004225480A1 (enExample) |
| CA (1) | CA2520181A1 (enExample) |
| WO (1) | WO2004087877A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| EP1613775B1 (en) * | 2003-03-26 | 2012-08-29 | Multicell Immunotherapeutics, Inc. | Selected rna motifs in anti-leukemia therapy |
| JP2008531672A (ja) * | 2005-03-02 | 2008-08-14 | イギリス国 | 医薬組成物 |
| EP2281043B1 (en) | 2008-04-25 | 2013-03-13 | Innate Pharma | Improved tlr3 agonist compositions |
| WO2011100769A2 (en) * | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Kinase modulators for the treatment of cancer |
| US20140335154A1 (en) * | 2013-03-12 | 2014-11-13 | Multicell Immunotherapeutics, Inc. | Methods and formulations to achieve tumor targeted double stranded rna mediated cell death |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US508386A (en) * | 1893-11-07 | hayworth | ||
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US5906980A (en) * | 1987-07-17 | 1999-05-25 | Hem Research Inc. | Treatment of hepatitis with mismatched dsRNA |
| US5683986A (en) * | 1987-08-12 | 1997-11-04 | Hemispherx Biopharma Inc. | Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment |
| US5593973A (en) * | 1987-09-04 | 1997-01-14 | Hemispherx Biopharma Inc. | Treatment of viral hepatitis with mismatched dsRNA |
| US5000000A (en) * | 1988-08-31 | 1991-03-19 | University Of Florida | Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes |
| EP0460076B1 (en) * | 1989-02-24 | 1995-11-29 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
| US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| ZA908037B (en) * | 1989-10-11 | 1991-09-25 | Hem Res Inc | Protection from shock subsequent to injury by double-standed rnas |
| US5969109A (en) * | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
| US5998366A (en) * | 1990-09-21 | 1999-12-07 | The Regents Of The University Of California | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5958457A (en) * | 1993-04-22 | 1999-09-28 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| DE69535243T2 (de) * | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| CA2560114A1 (en) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| GB9501079D0 (en) * | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
| WO1998000013A1 (en) * | 1996-06-28 | 1998-01-08 | The Regents Of The University Of California | Enhancement of cancer cell death |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| ATE370740T1 (de) * | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
| US6777546B2 (en) * | 1997-10-07 | 2004-08-17 | Loma Linda University | Methods and substances for preventing and treating autoimmune disease |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| DE10100586C1 (de) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| JP4304900B2 (ja) * | 2000-05-25 | 2009-07-29 | 富士ゼロックス株式会社 | 画像形成方法 |
| AU2001280934A1 (en) * | 2000-07-28 | 2002-02-13 | Alliance Pharmaceutical Corp. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| US6811785B2 (en) * | 2001-05-07 | 2004-11-02 | Mount Sinai School Of Medicine Of New York University | Multivalent MHC class II—peptide chimeras |
| CA2464889A1 (en) * | 2001-11-02 | 2003-05-08 | Sekisui Chemical Co., Ltd. | Cytokine-inducing material and cytokine-inducing instrument |
| CA2479187A1 (en) * | 2002-03-15 | 2003-09-25 | Astral, Inc. | Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| EP1556082A1 (en) * | 2002-10-22 | 2005-07-27 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
| EP1613775B1 (en) * | 2003-03-26 | 2012-08-29 | Multicell Immunotherapeutics, Inc. | Selected rna motifs in anti-leukemia therapy |
| WO2006014653A1 (en) * | 2004-07-20 | 2006-02-09 | Schering Corporation | Induction of apoptosis in toll-like receptor expressing tumor cells |
| WO2006054129A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
-
2004
- 2004-03-25 EP EP04758378A patent/EP1613775B1/en not_active Expired - Lifetime
- 2004-03-25 JP JP2006509328A patent/JP2006522806A/ja active Pending
- 2004-03-25 US US10/550,722 patent/US20060172959A1/en not_active Abandoned
- 2004-03-25 CN CNA2004800143531A patent/CN1795274A/zh active Pending
- 2004-03-25 AU AU2004225480A patent/AU2004225480A1/en not_active Abandoned
- 2004-03-25 WO PCT/US2004/009261 patent/WO2004087877A2/en not_active Ceased
- 2004-03-25 CA CA002520181A patent/CA2520181A1/en not_active Abandoned
-
2008
- 2008-11-14 US US12/271,779 patent/US20090169571A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004225480A1 (en) | 2004-10-14 |
| US20060172959A1 (en) | 2006-08-03 |
| WO2004087877A3 (en) | 2005-06-16 |
| JP2006522806A (ja) | 2006-10-05 |
| EP1613775A2 (en) | 2006-01-11 |
| EP1613775A4 (en) | 2009-10-21 |
| EP1613775B1 (en) | 2012-08-29 |
| US20090169571A1 (en) | 2009-07-02 |
| CN1795274A (zh) | 2006-06-28 |
| WO2004087877A2 (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nishikawa et al. | Enhanced immunostimulatory activity of oligodeoxynucleotides by Y‐shape formation | |
| Kariko et al. | Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development | |
| Marshall et al. | Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions | |
| Hornung et al. | Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides | |
| CA2817891C (en) | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response | |
| EP2341059A1 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| Ishii et al. | Innate immune recognition of nucleic acids: beyond toll‐like receptors | |
| CN107384930A (zh) | 非编码免疫调节dna 构建体 | |
| JP2007500018A (ja) | 安定化免疫調節オリゴヌクレオチド | |
| JP2007500018A6 (ja) | 安定化免疫調節オリゴヌクレオチド | |
| KR20120115412A (ko) | Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물 | |
| KR20000052994A (ko) | 면역촉진 핵산분자 | |
| US20090169571A1 (en) | Selected ma motifs to include cell death and/or apoptosis | |
| US10174326B2 (en) | TLR7 ligand and uses thereof | |
| EP4015636A1 (en) | 5' triphosphate oligonucleotide with blunt end and uses thereof | |
| JP2014532400A (ja) | 免疫賦活用の二本鎖ｒｎａ | |
| Furset et al. | Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule | |
| Campeau et al. | Intestinal epithelial cells modulate antigen-presenting cell responses to bacterial DNA | |
| Furset et al. | Impaired expression of indoleamine 2, 3‐dioxygenase in monocyte‐derived dendritic cells in response to Toll‐like receptor‐7/8 ligands | |
| AU2014205544A1 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| Coch et al. | Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA | |
| Sen et al. | The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity | |
| Matsuoka et al. | Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides | |
| Vollmer et al. | Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity | |
| Qiao et al. | Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |